v3.26.1
SEGMENT REPORTING (Details)
3 Months Ended 6 Months Ended
Jun. 30, 2026
USD ($)
Segment
Mar. 31, 2026
USD ($)
Jun. 30, 2025
USD ($)
Segment
Mar. 31, 2025
USD ($)
Jun. 30, 2026
USD ($)
Segment
Jun. 30, 2025
USD ($)
Segment
Segment Reporting [Abstract]            
Number of operating segments | Segment 1   1   1 1
Number of reportable segments | Segment 1   1   1 1
Segment Reporting Information [Line Items]            
Grant Revenue $ 227,629   $ 0   $ 227,629 $ 0
Research and development 1,304,345   116,383   2,054,158 191,915
Loss from operations 2,631,021   965,565   4,914,760 2,684,260
Net loss $ 2,373,800 $ 2,224,628 $ 957,825 $ 1,709,533 $ 4,598,428 $ 2,667,358
Number of reportable segments | Segment 1   1   1 1
Reportable Segment            
Segment Reporting Information [Line Items]            
Grant Revenue $ 227,629   $ 0   $ 227,629 $ 0
Professional services and Consulting 684,042   515,414   1,586,605 1,749,109
Personnel cost 428,922   180,933   863,980 432,041
Insurance expenses 123,574   130,521   242,657 259,474
Facility cost and other 90,138   22,314   167,360 51,721
Loss from operations 2,631,021   965,565   4,914,760 2,684,260
Interest income, net 29,592   7,740   88,703 16,902
Net loss 2,373,800   957,825   4,598,428 2,667,358
Reportable Segment | SP-3164            
Segment Reporting Information [Line Items]            
Research and development 0   8,406   15,160 29,443
Reportable Segment | SP-2577            
Segment Reporting Information [Line Items]            
Research and development 25,767   107,977   34,077 162,472
Reportable Segment | IMP3ACT (Designable Multi-Antivirals)            
Segment Reporting Information [Line Items]            
Research and development $ 1,278,578   $ 0   $ 2,004,921 $ 0